A Singapore-based biopharmaceutical company has raised £1.8m to market a natural medicine to treat stroke victims.
Moleac announced that it raised the money through a group of private investors who are based in both Europe and Asia, along with Hunza Ventures.
Moleac will use this injection of funds to market its first product NeuroAid(TM) on a global scale.
NeuroAid is a natural medicine developed in China. Clinical trials have shown that patients taking NeuroAid within six months of a stroke achieve better neurological and functional recovery.
The product is already listed in seven countries and is available worldwide through IDIS Pharmaceuticals.
Currently, Moleac is supporting the CHIMES society which implements a multi-centre clinical trial.
The study is looking at the efficacy of NeuroAid in improving independence in patients, with treatment starting within 48 hours of a stroke.
David Picard, CEO and co-founder of Moleac, said:
“Demonstrating the benefits of NeuroAid, when administered at the acute stage of a stroke, to the global market will enable it to become a systematic treatment modality. This is important, as there are currently no other drugs available to stroke patients, to help them during their recovery.”
Copyright © PA Business 2008